Note: Comprehensive training slide decks covering topics related to routine HIV testing in health care settings. Presentations include current HIV epidemiology in the United States, the scientific and public health rationale for the CDC recommendations, practical approaches to implementation, to the potential impact of scaled up testing on patient outcomes and health care costs. The slide decks are intended for health educators who have knowledge of HIV testing, and may serve as a companion to the online tutorial Routine HIV Screening in Health Care Settings ( www.HIVwebstudy.org ).

FDA has approved a new dosing regimen for Kaletra (lopinavir/ritonavir) tablets and oral solution. Kaletra can be administered once daily (800/200 mg) in patients with less than three lopinavir resistance associated substitutions. Once daily administration of Katetra is not recommended for adult patients with three or more of the following lopinavir resistance-associated substitutions: L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V. Also, once daily administration of Kaletra is not recommended in pediatric patients.

The complete revised label is available at the FDA Web site: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA